<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34696348</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>07</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>10</Issue><PubDate><Year>2021</Year><Month>Sep</Month><Day>24</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Application Route and Immune Status of the Host Determine Safety and Oncolytic Activity of Oncolytic Coxsackievirus B3 Variant PD-H.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1918</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v13101918</ELocationID><Abstract><AbstractText>The coxsackievirus B3 strain PD-0 has been proposed as a new oncolytic virus for the treatment of colorectal carcinoma. Here, we generated a cDNA clone of PD-0 and analyzed the virus PD-H, newly generated from this cDNA, in xenografted and syngenic models of colorectal cancer. Replication and cytotoxic assays revealed that PD-H replicated and lysed colorectal carcinoma cell lines in vitro as well as PD-0. Intratumoral injection of PD-H into subcutaneous DLD-1 tumors in nude mice resulted in strong inhibition of tumor growth and significantly prolonged the survival of the animals, but virus-induced systemic infection was observed in one of the six animals. In a syngenic mouse model of subcutaneously growing Colon-26 tumors, intratumoral administration of PD-H led to a significant reduction of tumor growth, the prolongation of animal survival, the prevention of tumor-induced cachexia, and the elevation of CD3<sup>+</sup> and dendritic cells in the tumor microenvironment. No virus-induced side effects were observed. After intraperitoneal application, PD-H induced weak pancreatitis and myocarditis in immunocompetent mice. By equipping the virus with target sites of miR-375, which is specifically expressed in the pancreas, organ infections were prevented. Moreover, employment of this virus in a syngenic mouse model of CT-26 peritoneal carcinomatosis resulted in a significant reduction in tumor growth and an increase in animal survival. The results demonstrate that the immune status of the host, the route of virus application, and the engineering of the virus with target sites of suitable microRNAs are crucial for the use of PD-H as an oncolytic virus.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hazini</LastName><ForeName>Ahmet</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Applied Biochemistry, Institute of Biotechnology, Technische Universität Berlin, 13355 Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oncology, University of Oxford, Oxford OX3 7DQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dieringer</LastName><ForeName>Babette</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Applied Biochemistry, Institute of Biotechnology, Technische Universität Berlin, 13355 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klingel</LastName><ForeName>Karin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-0203-2498</Identifier><AffiliationInfo><Affiliation>Cardiopathology, Institute for Pathology and Neuropathology, University Hospital Tuebingen, 72076 Tuebingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pryshliak</LastName><ForeName>Markian</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0001-8270</Identifier><AffiliationInfo><Affiliation>Department of Applied Biochemistry, Institute of Biotechnology, Technische Universität Berlin, 13355 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geisler</LastName><ForeName>Anja</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Applied Biochemistry, Institute of Biotechnology, Technische Universität Berlin, 13355 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kobelt</LastName><ForeName>Dennis</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-9373-0648</Identifier><AffiliationInfo><Affiliation>EPO GmbH Berlin-Buch, Robert-Rössle Str. 10, 13125 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daberkow</LastName><ForeName>Ole</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>EPO GmbH Berlin-Buch, Robert-Rössle Str. 10, 13125 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurreck</LastName><ForeName>Jens</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-1469-0052</Identifier><AffiliationInfo><Affiliation>Department of Applied Biochemistry, Institute of Biotechnology, Technische Universität Berlin, 13355 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Linthout</LastName><ForeName>Sophie van</ForeName><Initials>SV</Initials><AffiliationInfo><Affiliation>Berlin Institute of Health Center for Regenerative Therapies (BCRT), Campus Virchow Klinikum (CVK), Charité-Universitätsmedizin Berlin, Föhrer Str. 15, 13353 Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Cardiovascular Research (DZHK), Partner Site Berlin-Charité, Oudenarder Straße 16, 13316 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fechner</LastName><ForeName>Henry</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-7082-4350</Identifier><AffiliationInfo><Affiliation>Department of Applied Biochemistry, Institute of Biotechnology, Technische Universität Berlin, 13355 Berlin, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016466" MajorTopicYN="N">CHO Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015179" MajorTopicYN="N">Colorectal Neoplasms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003384" MajorTopicYN="N">Coxsackievirus Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003412" MajorTopicYN="N">Cricetulus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="N">Enterovirus</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009205" MajorTopicYN="N">Myocarditis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050504" MajorTopicYN="N">Oncolytic Viruses</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">PD</Keyword><Keyword MajorTopicYN="N">cancer</Keyword><Keyword MajorTopicYN="N">colorectal carcinoma</Keyword><Keyword MajorTopicYN="N">coxsackievirus B3</Keyword><Keyword MajorTopicYN="N">microRNAs</Keyword><Keyword MajorTopicYN="N">oncolytic virus</Keyword></KeywordList><CoiStatement>H.F. and A.H. have a patent pending for use of PD-0 and miR-TS in oncolytic CVB3. The other authors have no competing financial interest exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>9</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34696348</ArticleId><ArticleId IdType="pmc">PMC8539752</ArticleId><ArticleId IdType="doi">10.3390/v13101918</ArticleId><ArticleId IdType="pii">v13101918</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kelly E.J., Russell S.J. History of Oncolytic Viruses: Genesis to Genetic Engineering. Mol. Ther. 2007;15:651–659. doi: 10.1038/sj.mt.6300108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.mt.6300108</ArticleId><ArticleId IdType="pubmed">17299401</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman H.L., Kohlhapp F.J., Zloza A. Oncolytic viruses: A new class of immunotherapy drugs. Nat. Rev. Drug Discov. 2015;14:642–662. doi: 10.1038/nrd4663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd4663</ArticleId><ArticleId IdType="pmc">PMC7097180</ArticleId><ArticleId IdType="pubmed">26323545</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyamoto S., Inoue H., Nakamura T., Yamada M., Sakamoto C., Urata Y., Okazaki T., Marumoto T., Takahashi A., Takayama K., et al. Coxsackievirus B3 Is an Oncolytic Virus with Immunostimulatory Properties That Is Active against Lung Adenocarcinoma. Cancer Res. 2012;72:2609–2621. doi: 10.1158/0008-5472.CAN-11-3185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-11-3185</ArticleId><ArticleId IdType="pubmed">22461509</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng H., Liu H., de Silva T., Xue Y., Mohamud Y., Ng C.S., Qu J., Zhang J., Jia W.W., Lockwood W.W., et al. Coxsackievirus Type B3 Is a Potent Oncolytic Virus against KRAS-Mutant Lung Adenocarcinoma. Mol. Ther.-Oncolytics. 2019;14:266–278. doi: 10.1016/j.omto.2019.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omto.2019.07.003</ArticleId><ArticleId IdType="pmc">PMC6709373</ArticleId><ArticleId IdType="pubmed">31463367</ArticleId></ArticleIdList></Reference><Reference><Citation>Hazini A., Pryshliak M., Brückner V., Klingel K., Sauter M., Pinkert S., Kurreck J., Fechner H. Heparan Sulfate Binding Coxsackievirus B3 Strain PD: A Novel Avirulent Oncolytic Agent Against Human Colorectal Carcinoma. Hum. Gene Ther. 2018;29:1301–1314. doi: 10.1089/hum.2018.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/hum.2018.036</ArticleId><ArticleId IdType="pubmed">29739251</ArticleId></ArticleIdList></Reference><Reference><Citation>Geisler A., Hazini A., Heimann L., Kurreck J., Fechner H. Coxsackievirus B3—Its Potential as an Oncolytic Virus. Viruses. 2021;13:718. doi: 10.3390/v13050718.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13050718</ArticleId><ArticleId IdType="pmc">PMC8143167</ArticleId><ArticleId IdType="pubmed">33919076</ArticleId></ArticleIdList></Reference><Reference><Citation>Garmaroudi F.S., Marchant D., Hendry R., Luo H., Yang D., Ye X., Shi J., McManus B.M. Coxsackievirus B3 replication and pathogenesis. Future Microbiol. 2015;10:629–653. doi: 10.2217/fmb.15.5.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fmb.15.5</ArticleId><ArticleId IdType="pubmed">25865198</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowles N., Olsen E., Richardson P., Archard L. Detection of Coxsackie-B-virus-specific RNA sequences in myocardial biopsy samples from patients with myocarditis and dilated cardiomyopathy. Lancet. 1986;327:1120–1123. doi: 10.1016/S0140-6736(86)91837-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(86)91837-4</ArticleId><ArticleId IdType="pubmed">2871380</ArticleId></ArticleIdList></Reference><Reference><Citation>Pauschinger M., Doerner A., Kuehl U., Schwimmbeck P.L., Poller W., Kandolf R., Schultheiss H.P. Enteroviral RNA replication in the myo-cardium of patients with left ventricular dysfunction and clinically suspected myocarditis. Circulation. 1999;99:889–895. doi: 10.1161/01.CIR.99.7.889.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.99.7.889</ArticleId><ArticleId IdType="pubmed">10027811</ArticleId></ArticleIdList></Reference><Reference><Citation>Foulis A.K., Farquharson M.A., Cameron S.O., McGill M., Schönke H., Kandolf R. A search for the presence of the enteroviral capsid protein VP1 in pancreases of patients with Type 1 (insulin-dependent) diabetes and pancreases and hearts of infants who died of coxsackieviral myocarditis. Diabetologia. 1990;33:290–298. doi: 10.1007/BF00403323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00403323</ArticleId><ArticleId IdType="pubmed">2376300</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X.-H., Zhang J.-M., Han W., Chen H., Chen Y.-H., Wang F.-R., Wang J.-Z., Zhang Y.-Y., Mo X.-D., Chen Y., et al. Viral encephalitis after haplo-identical hematopoietic stem cell transplantation: Causative viral spectrum, characteristics, and risk factors. Eur. J. Haematol. 2017;98:450–458. doi: 10.1111/ejh.12855.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ejh.12855</ArticleId><ArticleId IdType="pubmed">28129450</ArticleId></ArticleIdList></Reference><Reference><Citation>Tracy S., Pirruccello S., Lane P.H., Reyna S.M., Gauntt C.J. Group B coxsackievirus myocarditis and pancreatitis: Connection between viral virulence phenotypes in mice. J. Med. Virol. 2000;62:70–81. doi: 10.1002/1096-9071(200009)62:1&lt;70::AID-JMV11&gt;3.0.CO;2-R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1096-9071(200009)62:1&lt;70::AID-JMV11&gt;3.0.CO;2-R</ArticleId><ArticleId IdType="pubmed">10935991</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinkert S., Dieringer B., Diedrich S., Zeichhardt H., Kurreck J., Fechner H. Soluble coxsackie- and adenovirus receptor (sCAR-Fc); a highly efficient compound against laboratory and clinical strains of coxsackie-B-virus. Antivir. Res. 2016;136:1–8. doi: 10.1016/j.antiviral.2016.10.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2016.10.010</ArticleId><ArticleId IdType="pubmed">27773751</ArticleId></ArticleIdList></Reference><Reference><Citation>Gnädig N.F., Beaucourt S., Campagnola G., Borderia A.V., Sanz-Ramos M., Gong P., Blanc H., Peersen O.B., Vignuzzi M. Coxsackievirus B3 mutator strains are attenuated in vivo. Proc. Natl. Acad. Sci. USA. 2012;109:E2294–E2303. doi: 10.1073/pnas.1204022109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1204022109</ArticleId><ArticleId IdType="pmc">PMC3427060</ArticleId><ArticleId IdType="pubmed">22853955</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasrado N., Gangaplara A., Massilamany C., Arumugam R., Shelbourn A., Rasquinha M.T., Basavalingappa R.H., Delhon G., Xiang S.-H., Pattnaik A.K., et al. Attenuated strain of CVB3 with a mutation in the CAR-interacting region protects against both myocarditis and pancreatitis. Sci. Rep. 2021;11:1–20. doi: 10.1038/s41598-021-90434-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-90434-w</ArticleId><ArticleId IdType="pmc">PMC8203608</ArticleId><ArticleId IdType="pubmed">34127684</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y., Wang W., Wan J., Yang Y., Fu W., Pan D., Cai L., Cheng T., Huang X., Wang Y. Oncolytic activity of a coxsackievirus B3 strain in human endometrial cancer cell lines. Virol. J. 2018;15:1–12. doi: 10.1186/s12985-018-0975-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-018-0975-x</ArticleId><ArticleId IdType="pmc">PMC5891967</ArticleId><ArticleId IdType="pubmed">29631630</ArticleId></ArticleIdList></Reference><Reference><Citation>Hazini A., Dieringer B., Pryshliak M., Knoch K.-P., Heimann L., Tolksdorf B., Pappritz K., El-Shafeey M., Solimena M., Beling A., et al. miR-375- and miR-1-Regulated Coxsackievirus B3 Has No Pancreas and Heart Toxicity But Strong Antitumor Efficiency in Colorectal Carcinomas. Hum. Gene Ther. 2021;32:216–230. doi: 10.1089/hum.2020.228.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/hum.2020.228</ArticleId><ArticleId IdType="pubmed">33481658</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia Y., Miyamoto S., Soda Y., Takishima Y., Sagara M., Liao J., Hirose L., Hijikata Y., Miura Y., Hara K., et al. Extremely Low Organ Toxicity and Strong Antitumor Activity of miR-34-Regulated Oncolytic Coxsackievirus B3. Mol. Ther.-Oncolytics. 2019;12:246–258. doi: 10.1016/j.omto.2019.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omto.2019.01.003</ArticleId><ArticleId IdType="pmc">PMC6406029</ArticleId><ArticleId IdType="pubmed">30891489</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagara M., Miyamoto S., Itoh S., Soda Y., Tani K. Development of New Oncolytic Virotherapy Targeting Breast Cancer Using Coxsackievirus B3. Anticancer Res. 2021;41:81–89. doi: 10.21873/anticanres.14753.</Citation><ArticleIdList><ArticleId IdType="doi">10.21873/anticanres.14753</ArticleId><ArticleId IdType="pubmed">33419801</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H., Xue Y.C., Deng H., Mohamud Y., Ng C.S., Chu A., Lim C.J., Lockwood W.W., Jia W.W., Luo H. MicroRNA Modification of Coxsackievirus B3 Decreases Its Toxicity, while Retaining Oncolytic Potency against Lung Cancer. Mol. Ther.-Oncolytics. 2020;16:207–218. doi: 10.1016/j.omto.2020.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omto.2020.01.002</ArticleId><ArticleId IdType="pmc">PMC7036525</ArticleId><ArticleId IdType="pubmed">32123721</ArticleId></ArticleIdList></Reference><Reference><Citation>Tonew M., Hartmann M., Schmidtke M., Stelzner A. Replication and persistence of Coxsackieviruses B3 in human fibroblasts. Zent. Bakteriol. 1995;282:92–101. doi: 10.1016/S0934-8840(11)80801-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0934-8840(11)80801-7</ArticleId><ArticleId IdType="pubmed">7734835</ArticleId></ArticleIdList></Reference><Reference><Citation>Zautner A.E., Koörner U., Henke A., Badorff C., Schmidtke M. Heparan Sulfates and Coxsackievirus-Adenovirus Receptor: Each One Mediates Coxsackievirus B3 PD Infection. J. Virol. 2003;77:10071–10077. doi: 10.1128/JVI.77.18.10071-10077.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.77.18.10071-10077.2003</ArticleId><ArticleId IdType="pmc">PMC224569</ArticleId><ArticleId IdType="pubmed">12941917</ArticleId></ArticleIdList></Reference><Reference><Citation>Zautner A.E., Jahn B., Hammerschmidt E., Wutzler P., Schmidtke M. N- and 6-O-Sulfated Heparan Sulfates Mediate Internalization of Coxsackievirus B3 Variant PD into CHO-K1 Cells. J. Virol. 2006;80:6629–6636. doi: 10.1128/JVI.01988-05.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01988-05</ArticleId><ArticleId IdType="pmc">PMC1488958</ArticleId><ArticleId IdType="pubmed">16775350</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandolf R., Hofschneider P.H. Molecular cloning of the genome of a cardiotropic Coxsackie B3 virus: Full-length reverse-transcribed recombinant cDNA generates infectious virus in mammalian cells. Proc. Natl. Acad. Sci. USA. 1985;82:4818–4822. doi: 10.1073/pnas.82.14.4818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.82.14.4818</ArticleId><ArticleId IdType="pmc">PMC390996</ArticleId><ArticleId IdType="pubmed">2410905</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinkert S., Pryshliak M., Pappritz K., Knoch K., Hazini A., Dieringer B., Schaar K., Dong F., Hinze L., Lin J., et al. Development of a new mouse model for coxsackievirus-induced myocarditis by attenuating coxsackievirus B3 virulence in the pancreas. Cardiovasc. Res. 2019;116:1756–1766. doi: 10.1093/cvr/cvz259.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvz259</ArticleId><ArticleId IdType="pubmed">31598635</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowlton K.U., Jeon E.S., Berkley N., Wessely R., Huber S. A mutation in the puff region of VP2 attenuates the myocarditic phenotype of an infectious cDNA of the Woodruff variant of coxsackievirus B3. J. Virol. 1996;70:7811–7818. doi: 10.1128/jvi.70.11.7811-7818.1996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.70.11.7811-7818.1996</ArticleId><ArticleId IdType="pmc">PMC190851</ArticleId><ArticleId IdType="pubmed">8892902</ArticleId></ArticleIdList></Reference><Reference><Citation>Slifka M.K., Pagarigan R., Mena I., Feuer R., Whitton J.L. Using Recombinant Coxsackievirus B3 To Evaluate the Induction and Protective Efficacy of CD8 + T Cells during Picornavirus Infection. J. Virol. 2001;75:2377–2387. doi: 10.1128/JVI.75.5.2377-2387.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.75.5.2377-2387.2001</ArticleId><ArticleId IdType="pmc">PMC114821</ArticleId><ArticleId IdType="pubmed">11160741</ArticleId></ArticleIdList></Reference><Reference><Citation>Klump W.M., Bergmann I., Müller B.C., Ameis D., Kandolf R. Complete nucleotide sequence of infectious Coxsackievirus B3 cDNA: Two initial 5′ uridine residues are regained during plus-strand RNA synthesis. J. Virol. 1990;64:1573–1583. doi: 10.1128/jvi.64.4.1573-1583.1990.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.64.4.1573-1583.1990</ArticleId><ArticleId IdType="pmc">PMC249292</ArticleId><ArticleId IdType="pubmed">2157045</ArticleId></ArticleIdList></Reference><Reference><Citation>Strassmann G., Masui Y., Chizzonite R., Fong M. Mechanisms of experimental cancer cachexia. Local involvement of IL-1 in colon-26 tumor. J. Immunol. 1993;150:2341–2345.</Citation><ArticleIdList><ArticleId IdType="pubmed">8450216</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonetto A., Rupert J.E., Barreto R., Zimmers T.A. The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia. J. Vis. Exp. 2016;117:e54893. doi: 10.3791/54893.</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/54893</ArticleId><ArticleId IdType="pmc">PMC5226332</ArticleId><ArticleId IdType="pubmed">27929469</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasumoto K., Mukaida N., Harada A., Kuno K., Akiyama M., Nakashima E., Fujioka N., Mai M., Kasahara T., Fujimoto-Ouchi K. Molecular analysis of the cytokine network involved in cachexia in colon 26 adenocarcinoma-bearing mice. Cancer Res. 1995;55:921–927.</Citation><ArticleIdList><ArticleId IdType="pubmed">7850809</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidtke M., Merkle I., Klingel K., Hammerschmidt E., Zautner A., Wutzler P. The viral genetic background determines the outcome of coxsackievirus B3 infection in outbred NMRI mice. J. Med. Virol. 2007;79:1334–1342. doi: 10.1002/jmv.20933.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.20933</ArticleId><ArticleId IdType="pubmed">17607777</ArticleId></ArticleIdList></Reference><Reference><Citation>Holland J.J., de la Torre J.C., Clarke D.K., Duarte E. Quantitation of relative fitness and great adaptability of clonal populations of RNA viruses. J. Virol. 1991;65:2960–2967. doi: 10.1128/jvi.65.6.2960-2967.1991.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.65.6.2960-2967.1991</ArticleId><ArticleId IdType="pmc">PMC240937</ArticleId><ArticleId IdType="pubmed">2033662</ArticleId></ArticleIdList></Reference><Reference><Citation>Bentley K., Evans D.J. Mechanisms and consequences of positive-strand RNA virus recombination. J. Gen. Virol. 2018;99:1345–1356. doi: 10.1099/jgv.0.001142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jgv.0.001142</ArticleId><ArticleId IdType="pubmed">30156526</ArticleId></ArticleIdList></Reference><Reference><Citation>Domingo E., Perales C. Viral quasispecies. PLoS Genet. 2019;15:e1008271. doi: 10.1371/journal.pgen.1008271.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1008271</ArticleId><ArticleId IdType="pmc">PMC6797082</ArticleId><ArticleId IdType="pubmed">31622336</ArticleId></ArticleIdList></Reference><Reference><Citation>Zainutdinov S.S., Kochneva G.V., Netesov S.V., Chumakov P.M., Matveeva O.V. Directed evolution as a tool for the selection of oncolytic RNA viruses with desired phenotypes. Oncolytic Virother. 2019;8:9–26. doi: 10.2147/OV.S176523.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OV.S176523</ArticleId><ArticleId IdType="pmc">PMC6636189</ArticleId><ArticleId IdType="pubmed">31372363</ArticleId></ArticleIdList></Reference><Reference><Citation>Grass V., Hardy E., Kobert K., Talemi S.R., Décembre E., Guy C., Markov P.V., Kohl A., Paris M., Böckmann A., et al. Adaptation to host cell environment during experimental evolution of Zika virus. BioRxiv. 2020 doi: 10.1101/2020.12.28.424577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.12.28.424577</ArticleId><ArticleId IdType="pmc">PMC9587232</ArticleId><ArticleId IdType="pubmed">36271143</ArticleId></ArticleIdList></Reference><Reference><Citation>Bao Q., Hotz-Wagenblatt A., Betts M.J., Hipp M., Hugo A., Pougialis G., Lei-Rossmann J., Löchelt M. Shared and cell type-specific adaptation strategies of Gag and Env yield high titer bovine foamy virus variants. Infect. Genet. Evol. 2020;82:104287. doi: 10.1016/j.meegid.2020.104287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.meegid.2020.104287</ArticleId><ArticleId IdType="pubmed">32179148</ArticleId></ArticleIdList></Reference><Reference><Citation>Szadvari I., Krizanova O., Babula P. Athymic Nude Mice as an Experimental Model for Cancer Treatment. Physiol. Res. 2016;65:S441–S453. doi: 10.33549/physiolres.933526.</Citation><ArticleIdList><ArticleId IdType="doi">10.33549/physiolres.933526</ArticleId><ArticleId IdType="pubmed">28006926</ArticleId></ArticleIdList></Reference><Reference><Citation>LeBlanc P.A., Scherer W.F., Sussdorf D.H. Infections of Congenitally Athymic (Nude) and Normal Mice with Avirulent and Virulent Strains of Venezuelan Encephalitis Virus. Infect. Immun. 1978;21:779–785. doi: 10.1128/iai.21.3.779-785.1978.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/iai.21.3.779-785.1978</ArticleId><ArticleId IdType="pmc">PMC422065</ArticleId><ArticleId IdType="pubmed">711332</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Nahass E.-S., El-Dakhly K., El-Habashi N., Anwar S.I., Sakai H., Hirata A., Okada A., Abo-Sakaya R., Fukushi H., Yanai T. Susceptibility of BALB/c-nu/nu Mice and BALB/c Mice to Equine Herpesvirus 9 Infection. Vet. Pathol. 2013;51:581–590. doi: 10.1177/0300985813493932.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0300985813493932</ArticleId><ArticleId IdType="pubmed">23804999</ArticleId></ArticleIdList></Reference><Reference><Citation>Lane T.E., Paoletti A.D., Buchmeier M.J. Disassociation between the in vitro and in vivo effects of nitric oxide on a neurotropic murine coronavirus. J. Virol. 1997;71:2202–2210. doi: 10.1128/jvi.71.3.2202-2210.1997.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.71.3.2202-2210.1997</ArticleId><ArticleId IdType="pmc">PMC191327</ArticleId><ArticleId IdType="pubmed">9032354</ArticleId></ArticleIdList></Reference><Reference><Citation>Pryshliak M., Hazini A., Knoch K., Dieringer B., Tolksdorf B., Solimena M., Kurreck J., Pinkert S., Fechner H. MiR-375-mediated suppression of engineered coxsackievirus B3 in pancreatic cells. FEBS Lett. 2019;594:763–775. doi: 10.1002/1873-3468.13647.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1873-3468.13647</ArticleId><ArticleId IdType="pubmed">31643074</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamarin D., Holmgaard R.B., Subudhi S., Park J.S., Mansour M., Palese P., Merghoub T., Wolchok J.D., Allison J.P. Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy. Sci. Transl. Med. 2014;6:226ra32. doi: 10.1126/scitranslmed.3008095.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3008095</ArticleId><ArticleId IdType="pmc">PMC4106918</ArticleId><ArticleId IdType="pubmed">24598590</ArticleId></ArticleIdList></Reference><Reference><Citation>Toda M., Rabkin S.D., Kojima H., Martuza R.L. Herpes Simplex Virus as an in Situ Cancer Vaccine for the Induction of Specific Anti-Tumor Immunity. Hum. Gene Ther. 1999;10:385–393. doi: 10.1089/10430349950018832.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/10430349950018832</ArticleId><ArticleId IdType="pubmed">10048391</ArticleId></ArticleIdList></Reference><Reference><Citation>Workenhe S.T., Simmons G., Pol J.G., Lichty B.D., Halford W.P., Mossman K.L. Immunogenic HSV-mediated Oncolysis Shapes the Antitumor Immune Response and Contributes to Therapeutic Efficacy. Mol. Ther. 2014;22:123–131. doi: 10.1038/mt.2013.238.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2013.238</ArticleId><ArticleId IdType="pmc">PMC3978812</ArticleId><ArticleId IdType="pubmed">24343053</ArticleId></ArticleIdList></Reference><Reference><Citation>Annels N.E., Arif M., Simpson G., Denyer M., Moller-Levet C., Mansfield D., Butler R., Shafren D., Au G., Knowles M., et al. Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus. Mol. Ther.-Oncolytics. 2018;9:1–12. doi: 10.1016/j.omto.2018.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omto.2018.02.001</ArticleId><ArticleId IdType="pmc">PMC6035483</ArticleId><ArticleId IdType="pubmed">29989024</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin N.T., Bell J.C. Oncolytic Virus Combination Therapy: Killing One Bird with Two Stones. Mol. Ther. 2018;26:1414–1422. doi: 10.1016/j.ymthe.2018.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2018.04.001</ArticleId><ArticleId IdType="pmc">PMC5986726</ArticleId><ArticleId IdType="pubmed">29703699</ArticleId></ArticleIdList></Reference><Reference><Citation>Argiles J.M., Busquets S., Stemmler B., López-Soriano F.J. Cancer cachexia: Understanding the molecular basis. Nat. Rev. Cancer. 2014;14:754–762. doi: 10.1038/nrc3829.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc3829</ArticleId><ArticleId IdType="pubmed">25291291</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu W., Neill T.J., Yang Y., Hu Z., Cleveland E., Wu Y., Hutten R., Xiao X., Stock S.R., Shevrin D.H., et al. The systemic delivery of an oncolytic adenovirus expressing decorin inhibits bone metastasis in a mouse model of human prostate cancer. Gene Ther. 2014;22:247–256. doi: 10.1038/gt.2014.110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gt.2014.110</ArticleId><ArticleId IdType="pmc">PMC4361227</ArticleId><ArticleId IdType="pubmed">25503693</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett J.J., Kooby D.A., Delman K., McAuliffe P., Halterman M.W., Federoff H., Fong Y. Antitumor efficacy of regional oncolytic viral therapy for peritoneally disseminated cancer. J. Mol. Med. 2000;78:166–174. doi: 10.1007/s001090000092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s001090000092</ArticleId><ArticleId IdType="pubmed">10868479</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly K.J., Woo Y., Brader P., Yu Z., Riedl C., Lin S.-F., Chen N., Yu Y.A., Rusch V., Szalay A.A., et al. Novel Oncolytic Agent GLV-1h68 Is Effective Against Malignant Pleural Mesothelioma. Hum. Gene Ther. 2008;19:774–782. doi: 10.1089/hum.2008.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/hum.2008.036</ArticleId><ArticleId IdType="pmc">PMC2940611</ArticleId><ArticleId IdType="pubmed">18754710</ArticleId></ArticleIdList></Reference><Reference><Citation>Baracos V.E., Martin L., Korc M., Guttridge D.C., Fearon K.C.H. Cancer-associated cachexia. Nat. Rev. Dis. Prim. 2018;4:1–18. doi: 10.1038/nrdp.2017.105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.105</ArticleId><ArticleId IdType="pubmed">29345251</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonçalves R.D.C., Freire P.P., Coletti D., Seelaender M. Tumor Microenvironment Autophagic Processes and Cachexia: The Missing Link? Front. Oncol. 2020;10:1–7. doi: 10.3389/fonc.2020.617109.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2020.617109</ArticleId><ArticleId IdType="pmc">PMC7884816</ArticleId><ArticleId IdType="pubmed">33604297</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>